GlassScriptPhysician profile
Boris Khamishon
NPI 1104922038
$17,516.04
in general payments reported to CMS, 2019-2025
41 companies · $3,471 in 2025
The $3,471 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,250 · 2020: $1,396 · 2021: $2,723 · 2022: $2,466 · 2023: $2,740 · 2024: $3,470 · 2025: $3,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,587 · Education: $94.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,586.80 |
| Education | $94.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,986.88 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Neurelis, INC. | $2,176.03 | 2020-2025 | Valtoco |
| Abbvie INC. | $1,963.95 | 2021-2025 | |
| Sk Life Science, INC. | $1,800.21 | 2020-2025 | |
| Eisai INC. | $1,327.22 | 2019-2025 | |
| Biogen, INC. | $973.43 | 2020-2025 | Vumerity, Leqembi, Tysabri |
| Sunovion Pharmaceuticals INC. | $536.86 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $396.36 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $382.00 | 2022-2025 | Amvuttra, Onpattro |
| Catalyst Pharmaceuticals, INC. | $377.25 | 2023-2025 | Fycompa |
| Lilly USA, LLC | $351.68 | 2021-2025 | Kisunla, Amyvid |
| Sumitomo Pharma America, INC. | $340.42 | 2023-2024 | Aptiom |
| Greenwich Biosciences, INC. | $323.61 | 2019-2021 | |
| Lundbeck LLC | $297.00 | 2020-2025 | Rexulti, Vyepti |
| Otsuka America Pharmaceutical, INC. | $290.71 | 2023-2025 | Rexulti |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Khamishon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.